News & Updates

Using the Steno T1 Risk Engines, the dual SGLT*1 and SGLT2 inhibitor sotagliflozin showed potential in reducing the risk of cardiovascular (CV) and renal disease in adults with type 1 diabetes (T1D).

The use of metformin, fluvoxamine, or ivermectin in an outpatient setting did not appear to prevent progression to severe COVID-19, according to results of the phase III COVID-OUT trial.  

In a systematic review, a link between food insecurity (ie, low or very low food security) and obesity or greater weight gain was observed in early childhood. Some studies have pointed to an association specifically in girls and in children experiencing food insecurity at multiple timepoints.

Neurodevelopment appears to be significantly delayed at up to 4 years of age in boys who are born to mothers with gestational diabetes mellitus (GDM), reports a recent study.

Among patients with type 2 diabetes (T2D), the use of sodium-glucose cotransporter 2 inhibitors {SGLT2i) does not appear to increase the risk of lower-limb amputation, a recent study has found.

Individuals who are diagnosed with type 2 diabetes (T2D) at age ≤40 years have a greater risk of cardiovascular disease (CVD) and mortality than same-aged individuals without T2D or individuals diagnosed with T2D in later life, according to a study from Korea presented at EASD 2022.

Among patients with type 1 diabetes (T1D), alterations in plasma glutamate levels and free amino acid profiles are distinct than that in type 2 diabetes (T2D) patients and healthy controls, a recent study has found.